tetano
Editor, Senior Moderator
JCI Insight
. 2026 Jan 23;11(2):e198244.
doi: 10.1172/jci.insight.198244.
Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death
Olivia Lenoir[SUP] 1 [/SUP], Florence Morin[SUP] 2 [/SUP], Anouk Walter-Petrich[SUP] 3 [/SUP], Léa Resmini[SUP] 1 [/SUP], Mohamad Zaidan[SUP] 4 5 [/SUP], Nassim Mahtal[SUP] 1 [/SUP], Sophie Ferlicot[SUP] 6 [/SUP], Victor G Puelles[SUP] 7 8 [/SUP], Nicola Wanner[SUP] 7 8 [/SUP], Julien Dang[SUP] 1 [/SUP], Thibaut d'Izarny-Gargas[SUP] 1 [/SUP], Jana Biermann[SUP] 9 10 11 [/SUP], Benjamin Izar[SUP] 9 10 11 [/SUP], Stéphanie Baron[SUP] 12 13 [/SUP], Benjamin Terrier[SUP] 1 14 [/SUP], Ziad A Massy[SUP] 15 [/SUP], Marie Essig[SUP] 15 [/SUP], Aymeric Couturier[SUP] 15 [/SUP], Olivia May[SUP] 16 [/SUP], Xavier Belenfant[SUP] 16 [/SUP], David Buob[SUP] 17 [/SUP], Isabelle Brocheriou[SUP] 18 [/SUP], Hassan Izzedine[SUP] 19 [/SUP], Yannis Lombardi[SUP] 20 [/SUP], Hélène François[SUP] 20 [/SUP], Anissa Moktefi[SUP] 21 [/SUP], Vincent Audard[SUP] 22 23 [/SUP], Aurélie Sannier[SUP] 24 [/SUP], Eric Daugas[SUP] 25 [/SUP], Matthieu Jamme[SUP] 26 [/SUP], Guylaine Henry[SUP] 2 [/SUP], Isabelle Le Monnier de Gouville[SUP] 2 [/SUP], Catherine Marie[SUP] 2 [/SUP], Laurence Homyrda[SUP] 2 [/SUP], Céline Verstuyft[SUP] 27 [/SUP], Sarah Tubiana[SUP] 28 29 [/SUP], Ouifiya Kafif[SUP] 28 [/SUP], Valentine Piquard[SUP] 28 [/SUP], Maxime Dougados[SUP] 30 31 [/SUP], Tobias B Huber[SUP] 7 8 [/SUP], Marine Livrozet[SUP] 32 [/SUP], Jean-Sébastien Hulot[SUP] 1 32 [/SUP], Cedric Laouénan[SUP] 29 33 [/SUP], Jade Ghosn[SUP] 29 34 [/SUP], France Mentré[SUP] 29 33 [/SUP], Alexandre Karras[SUP] 1 35 [/SUP], Yazdan Yazdanpanah[SUP] 34 36 37 [/SUP], Raphaël Porcher[SUP] 38 39 [/SUP], Philippe Ravaud[SUP] 38 [/SUP], Sophie Caillat-Zucman[SUP] 2 40 [/SUP], Xavier Mariette[SUP] 41 [/SUP], Olivier Hermine[SUP] 42 43 [/SUP], Matthieu Resche-Rigon[SUP] 3 [/SUP], Pierre-Louis Tharaux[SUP] 1 [/SUP]; CORIMUNO-19 collaborative group
Affiliations
BACKGROUNDAfter identifying 2 immunomarkers of acute injury, KIM-1 and LCN2, in all kidney biopsies from 31 patients with COVID-19 pneumonia and de novo kidney dysfunction, we investigated whether circulating markers of kidney epithelial injury are common in patients with laboratory-confirmed COVID-19 who require oxygen support but do not have critical illness.METHODSWe studied 196 patients admitted to 15 hospitals with moderate to severe pneumonia who were enrolled in 2 independent randomized clinical trials. We measured 41 immune mediators and markers of kidney and endothelial injury in peripheral blood in these patients within 24 hours of randomization.RESULTSWe constructed a generalized linear CORIMUNO model combining serum levels of KIM-1, LCN2, IL-10, and age at hospital admission that showed high discrimination for mortality (derivation cohort: AUC = 0.82, 95% CI: 0.73-0.92; validation cohort: AUC = 0.83, 95% CI: 0.74-0.92). An early rise in circulating kidney injury markers, in the absence of acute kidney injury criteria, was markedly associated with the risk of developing a severe form of COVID-19 and death within 3 months.CONCLUSIONThe CORIMUNO score may be a helpful tool for risk stratification, and for the first time to our knowledge, it identifies the overlooked impact of subclinical kidney injury on pneumonia outcomes.TRIAL REGISTRATIONClinicalTrials.gov NCT04324047, NCT04324073, and NCT04331808.FUNDINGThis research was funded by the French Ministry of Health, Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0151, PHRC COVID-19-20-0029), Fondation de l'Assistance Publique Hôpitaux de Paris (Alliance Tous Unis Contre le Virus), Assistance Publique Hôpitaux de Paris, and grants from the Fondation pour la Recherche Médicale (FRM) (REA202010012514) and Agence Nationale de Recherches sur le Sida and emerging infectious diseases (ANRS) (ANRS0147) from the VINTED sponsorship.
Keywords: COVID-19; Clinical trials; Infectious disease; Nephrology; Outcomes research; Pulmonology.
. 2026 Jan 23;11(2):e198244.
doi: 10.1172/jci.insight.198244.
Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death
Olivia Lenoir[SUP] 1 [/SUP], Florence Morin[SUP] 2 [/SUP], Anouk Walter-Petrich[SUP] 3 [/SUP], Léa Resmini[SUP] 1 [/SUP], Mohamad Zaidan[SUP] 4 5 [/SUP], Nassim Mahtal[SUP] 1 [/SUP], Sophie Ferlicot[SUP] 6 [/SUP], Victor G Puelles[SUP] 7 8 [/SUP], Nicola Wanner[SUP] 7 8 [/SUP], Julien Dang[SUP] 1 [/SUP], Thibaut d'Izarny-Gargas[SUP] 1 [/SUP], Jana Biermann[SUP] 9 10 11 [/SUP], Benjamin Izar[SUP] 9 10 11 [/SUP], Stéphanie Baron[SUP] 12 13 [/SUP], Benjamin Terrier[SUP] 1 14 [/SUP], Ziad A Massy[SUP] 15 [/SUP], Marie Essig[SUP] 15 [/SUP], Aymeric Couturier[SUP] 15 [/SUP], Olivia May[SUP] 16 [/SUP], Xavier Belenfant[SUP] 16 [/SUP], David Buob[SUP] 17 [/SUP], Isabelle Brocheriou[SUP] 18 [/SUP], Hassan Izzedine[SUP] 19 [/SUP], Yannis Lombardi[SUP] 20 [/SUP], Hélène François[SUP] 20 [/SUP], Anissa Moktefi[SUP] 21 [/SUP], Vincent Audard[SUP] 22 23 [/SUP], Aurélie Sannier[SUP] 24 [/SUP], Eric Daugas[SUP] 25 [/SUP], Matthieu Jamme[SUP] 26 [/SUP], Guylaine Henry[SUP] 2 [/SUP], Isabelle Le Monnier de Gouville[SUP] 2 [/SUP], Catherine Marie[SUP] 2 [/SUP], Laurence Homyrda[SUP] 2 [/SUP], Céline Verstuyft[SUP] 27 [/SUP], Sarah Tubiana[SUP] 28 29 [/SUP], Ouifiya Kafif[SUP] 28 [/SUP], Valentine Piquard[SUP] 28 [/SUP], Maxime Dougados[SUP] 30 31 [/SUP], Tobias B Huber[SUP] 7 8 [/SUP], Marine Livrozet[SUP] 32 [/SUP], Jean-Sébastien Hulot[SUP] 1 32 [/SUP], Cedric Laouénan[SUP] 29 33 [/SUP], Jade Ghosn[SUP] 29 34 [/SUP], France Mentré[SUP] 29 33 [/SUP], Alexandre Karras[SUP] 1 35 [/SUP], Yazdan Yazdanpanah[SUP] 34 36 37 [/SUP], Raphaël Porcher[SUP] 38 39 [/SUP], Philippe Ravaud[SUP] 38 [/SUP], Sophie Caillat-Zucman[SUP] 2 40 [/SUP], Xavier Mariette[SUP] 41 [/SUP], Olivier Hermine[SUP] 42 43 [/SUP], Matthieu Resche-Rigon[SUP] 3 [/SUP], Pierre-Louis Tharaux[SUP] 1 [/SUP]; CORIMUNO-19 collaborative group
Affiliations
- PMID: 41574613
- DOI: 10.1172/jci.insight.198244
BACKGROUNDAfter identifying 2 immunomarkers of acute injury, KIM-1 and LCN2, in all kidney biopsies from 31 patients with COVID-19 pneumonia and de novo kidney dysfunction, we investigated whether circulating markers of kidney epithelial injury are common in patients with laboratory-confirmed COVID-19 who require oxygen support but do not have critical illness.METHODSWe studied 196 patients admitted to 15 hospitals with moderate to severe pneumonia who were enrolled in 2 independent randomized clinical trials. We measured 41 immune mediators and markers of kidney and endothelial injury in peripheral blood in these patients within 24 hours of randomization.RESULTSWe constructed a generalized linear CORIMUNO model combining serum levels of KIM-1, LCN2, IL-10, and age at hospital admission that showed high discrimination for mortality (derivation cohort: AUC = 0.82, 95% CI: 0.73-0.92; validation cohort: AUC = 0.83, 95% CI: 0.74-0.92). An early rise in circulating kidney injury markers, in the absence of acute kidney injury criteria, was markedly associated with the risk of developing a severe form of COVID-19 and death within 3 months.CONCLUSIONThe CORIMUNO score may be a helpful tool for risk stratification, and for the first time to our knowledge, it identifies the overlooked impact of subclinical kidney injury on pneumonia outcomes.TRIAL REGISTRATIONClinicalTrials.gov NCT04324047, NCT04324073, and NCT04331808.FUNDINGThis research was funded by the French Ministry of Health, Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0151, PHRC COVID-19-20-0029), Fondation de l'Assistance Publique Hôpitaux de Paris (Alliance Tous Unis Contre le Virus), Assistance Publique Hôpitaux de Paris, and grants from the Fondation pour la Recherche Médicale (FRM) (REA202010012514) and Agence Nationale de Recherches sur le Sida and emerging infectious diseases (ANRS) (ANRS0147) from the VINTED sponsorship.
Keywords: COVID-19; Clinical trials; Infectious disease; Nephrology; Outcomes research; Pulmonology.